|Bid||4.40 x 800|
|Ask||5.36 x 800|
|Day's Range||4.3000 - 5.2700|
|52 Week Range||2.1500 - 9.9000|
|Beta (3Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 11, 2019 - Mar 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
NEW YORK, NY / ACCESSWIRE / January 15, 2019 / Wall Street extended losses on Monday as concerns of a global economic slowdown were reignited on weaker-than-expected economic data from China. In December, ...
CAMPBELL, Calif., Jan. 14, 2019 -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that results from a new study evaluating the.
Although VIVUS (VVUS) is struggling with its legacy products, promotional initiatives and addition of cash-flow positive assets bode well for the company.
CAMPBELL, Calif., Dec. 27, 2018 -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of.
If you want to know who really controls VIVUS, Inc. (NASDAQ:VVUS), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, institutions Read More...
There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. ...
Vivus (VVUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Campbell, California-based company said it had a loss of 87 cents per share. The biopharmaceutical company posted revenue of $18.1 million in the period. In the final minutes of trading on Thursday, ...
Company to host conference call today at 4:30pm ET CAMPBELL, Calif., Nov. 01, 2018 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company.
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, today announced that Karen Ferrell and Edward A. Kangas have been appointed to VIVUS’ board of directors. “We welcome Karen and Ed, both of whom bring significant board experience including corporate governance, healthcare, managed care, finance and pharmaceuticals,” said John Amos, Chief Executive Officer at VIVUS.
CORAL GABLES, FL / ACCESSWIRE / September 11, 2018 / Biotech stocks continue to present key drivers of returns for many investors. Public equities have delivered strong returns underpinned by large-scale of monetary policy support. It is particularly noteworthy that the California Public Employees' Retirement System is considering the creation of a direct investment program, which would include investment in companies within sectors like healthcare and biotechnology.